Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IPX066 Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

NCT01468012
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa carbidopa and entacapone (LCE), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
View directory record Official record
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

NCT00203177
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, rasagiline mesylate 1.0 mg
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional

Timing of Levodopa Treatment in Parkinson's Disease

NCT00004733
View directory record Official record
Conditions
Parkinson's Disease
Interventions
levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:13 PM EDT
Withdrawn Phase 4 Interventional

Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation

NCT02346630
View directory record Official record
Conditions
Stroke
Interventions
Placebo, Levodopa / Carbidopa, Armeo
Drug · Device
Lead sponsor
Ross D. Zafonte, MD
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 2, 2026, 5:13 PM EDT
Completed No phase listed Observational

Influence of Theta Burst Stimulation and Carbidopa-Levodopa on Motor Performance in Stroke Patients

NCT00366184
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 4 Interventional Results available

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

NCT01770145
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
Interventions
APOKYN, L-dopa, Trimethobenzamide
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 2, 2026, 5:13 PM EDT
Recruiting Not applicable Interventional

Real-Time Levodopa Level Monitoring in Parkinson Disease

NCT04735627
View directory record Official record
Conditions
Parkinson Disease
Interventions
Levodopameter
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727
View directory record Official record
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

NCT03496870
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone, Carbidopa Levodopa
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Glendale, California • Long Beach, California • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

NCT03665454
View directory record Official record
Conditions
Parkinson Disease
Interventions
PF-06412562, Standard of Care Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

NCT03781167
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

NCT00869791
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 2, 2026, 5:13 PM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm

NCT06587217
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

NCT04379050
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Sun City, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

Levodopa for the Treatment of Residual Amblyopia

NCT01190813
View directory record Official record
Conditions
Amblyopia
Interventions
Levodopa/Carbidopa, Placebo, Patching
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 2Phase 3 Interventional

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

NCT00955045
View directory record Official record
Conditions
Parkinson's Disease
Interventions
istradefylline
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

NCT03007888
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Sinemet, IPX203
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Naples, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

NCT03887884
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, Sinemet
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

NCT00974974
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 2 Interventional

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 2, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 2, 2026, 5:13 PM EDT